Abstract
With their ability to differentiate and become an ongoing source of cells that
make up critical tissues and organs, stem cells have potential for new
regenerative therapies and as new research tools for drug developers to test
emerging therapies on diseased cells.
For market-watchers in the pharmaceutical industry, the question is what
potential they have and where they could take the market. Kalorama Information
has tackled that question in Stem Cells: Worldwide Markets for
Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst
Alison Sahoo has built models to determine the best, moderate and worst case
scenarios for the three key markets for stem cells:
- Stem Cell Therapeutics (Transplantation)
- Cord Blood Banking and
- Drug development
This report breaks down forecasted revenues and procedure volumes for stem
cell technologies for these segments in the following disease areas:
- Cardiovascular disease
- Lung disease
- Arthritis
- Incontinence
- Osteoporosis
- Diabetes
- Cancer
- Orthopedics
- Infertility
- Alzheimer' s disease
- Burns (severe)
- Lupus
- Parkinson' s disease
- Liver failure
- Multiple sclerosis
- Critical limb ischemia
- Crohn' s disease
- Sickle cell disease
- Multiple myeloma
- NH lymphoma
- Leukemia
Ths report is the result of exclusive interviews with executives in the stem
cell industry, a review of medical and company literature, government
databases and publications. As part of this comprehensive analysis of stem
cell markets, the following companies were profiled:
- Aastrom Biosciences
- Advanced Cell Technologies
- Brainstorm Cell Therapeutics
- Celegene
- Cord Blood America
- Cord Blood Registry
- Cryo-Cell International
- ES Cell International
- Geron
- Harvest Technologies
- Invitrogen
- Medistem
- Neostem
- Opexa Therapeutics
- Osiris Therapeutics
- Plureon
- Regenetech
- Revivicor
- Stem Cell Sciences
- StemLifeLine
- ThermoGenesis
- VetCell Bioscience
- ViaCell
| 
View Cart
